Immutep refocuses efti on HNSCC and sarcoma after trial failure
Immutep has outlined a narrowed clinical development strategy for its lead immunotherapy candidate eftilagimod alfa (efti), directing future registration-directed studies toward head and neck squamous cell carcinoma (HNSCC) in PD-L1-negative patients and the neoadjuvant setting of soft tissue sarcoma (STS). The announcement follows the earlier discontinuation of the TACTI-004 study and is accompanied by a manufacturing corrective action that the company says it believes addresses the root cause of that trial's unexpected outcome.
The Sydney and NASDAQ-listed company said its ongoing root cause analysis has identified structural differences between efti produced at 200-litre scale and the 2,000-litre scale material used exclusively in TACTI-004. Specifically, Immutep noted a subtle variation in N-glycan structure between the two batches, which it considers potentially relevant given the markedly different immune activation profile observed in TACTI-004 relative to earlier trials. A new manufacturing run at the 200-litre scale has been contracted; ten GMP batches produced at that scale were used in prior Phase I and Phase II studies, including TACTI-mel, TACTI-002 and INSIGHT-003, all of which generated data the company characterises as encouraging.
Regulatory footing and trial timeline
The refocused programme carries meaningful regulatory support. Efti holds FDA Fast Track designation in first-line HNSCC and received Orphan Drug Designation for STS in April 2026. Chief executive Marc Voigt said the company believes there is "a scientifically and clinically justified path to continue development," citing consistent immune activation data across multiple tumour types and constructive FDA interactions. Preparations for the next trials have begun, with a study start targeted for the second half of calendar year 2027, subject to final decisions on design, regulatory engagement, manufacturing timelines, partnering, and available resources.
Licensing partner Dr. Reddy's Laboratories has indicated support for the approach. Immutep also disclosed it is in preliminary discussions with additional parties regarding the proposed development pathway, suggesting the company is seeking either co-development arrangements or additional funding before committing to a full registrational programme.
Market context and competitive read-across
The two indications Immutep has chosen reflect genuine unmet need. In HNSCC, patients with a Combined Positive Score below 1 are ineligible for approved checkpoint inhibitors such as pembrolizumab, leaving a population with few systemic options beyond platinum-based chemotherapy. That subgroup framing also positions efti away from direct head-to-head competition with established anti-PD-1 agents. In STS, the neoadjuvant space is similarly sparse; no immunotherapy has received regulatory approval in that setting, and orphan designation provides both commercial incentives and a more manageable path to registration.
The manufacturing explanation for TACTI-004, if substantiated by the completed root cause analysis, matters considerably for investor confidence. Scale-dependent glycosylation changes are a recognised risk in biological manufacturing, and the scientific rationale is credible. However, the analysis remains ongoing and Immutep cautioned that further investigation of smaller inter-batch differences continues. Regulators will scrutinise the comparability data between 200-litre and 2,000-litre batches closely before any IND interaction proceeds.
Immutep's LAG-3 portfolio also includes IMP761, an agonist anti-LAG-3 antibody being developed for autoimmune disease, which the company said continues to advance in line with previously disclosed plans, providing a degree of pipeline diversification beyond the oncology programmes.
The 2H 2027 study start target leaves the company with roughly a year of preparation work, during which partnering outcomes and manufacturing readiness will be the decisive near-term milestones for investors to track.